Fatty liver breakthrough? scientists target epigenetic switches
NCT ID NCT06332677
First seen Apr 10, 2026 · Last updated May 17, 2026 · Updated 4 times
Summary
This study looks at whether blocking two proteins, SUV420H1 and SUV420H2, in liver cells can protect against nonalcoholic fatty liver disease (NAFLD). Researchers will test this in mice, analyze human genetic data, and try a new gene-silencing approach in lab-grown human liver tissue. The goal is to find a new treatment target for a condition that affects millions worldwide.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NAFLD are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Istituto di Ricovero e Cura a Carattere Scientifico di natura pubblica
RECRUITINGMilan, 20122, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.